Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01452152 · ClinicalTrials.gov registry record · Phase 4
Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study
A Phase 4 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
NCT01452152 is a Phase 4 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 9 participants.
The verdict
NCT01452152, a Phase 4 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
Study Summary
It is standard treatment to take anti-platelet medication after cardiac catheterization and stent placement to help prevent the formation of blood clots that may cause heart attack or stroke. The most commonly used anti-platelet medicine is clopidogrel (Plavix®). However, researchers have found that people vary in their response to clopidogrel, in part because of differences in their genes. Prasugrel (Effient®)is another anti-platelet medication used to prevent clots. The genetic differences that affect clopidogrel response do not affect prasugrel response. Recently, the FDA added a warning to the label of clopidogrel to notify doctors and patients with certain genetic differences may not get the full benefit from clopidogrel. Despite this, genetic testing for these variations is not usually done in standard medical practice. The purpose of this study is to see if patients with certain gene differences have fewer major cardiac events after stent placement if they are given anti-platelet therapy guided by their individual genetic type compared to standard anti-platelet therapy.
Interventions
- DRUG clopidogrel
- DRUG prasugrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-02 |
| Est. Completion | 2013-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01452152
The ClinicalTrials.gov registry entry for NCT01452152 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which clopidogrel is the first listed.
NCT01452152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01452152 about?
NCT01452152 is a clinical study titled "Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study". It is standard treatment to take anti-platelet medication after cardiac catheterization and stent placement to help prevent the formation of blood clots that may cause heart attack or stroke. The most commonly used anti-platelet medicine is clopidogrel (Plavix®). However, researchers have found that...
What is the current status of trial NCT01452152?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2012-02. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01452152?
The interventions under investigation include: clopidogrel (DRUG), prasugrel (DRUG).
Who is sponsoring clinical trial NCT01452152?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.